Literature DB >> 19171021

Further validation of a pruritus severity scale for use in dogs.

J Rybnícek1, P J Lau-Gillard, R Harvey, P B Hill.   

Abstract

A scale to assess the severity of pruritus in dogs was further validated. Comparison of the scale with one containing visible numerical markings demonstrated that owners were heavily influenced by the presence of numbers, resulting in a loss of the scale's ability to generate continuous data. The presence of a traditional visual analogue scale was therefore essential. The scale was tested on 713 owners who presented their dogs for veterinary attention. Pruritus scores in 408 dogs with skin disease covered the full range of possible values (0 to 10). In 305 dogs with no skin disease, 90 owners gave a score greater than zero. Comparison of the scores seen in pruritic dogs, and dogs with no evidence of skin disease, allowed a 'normal range' of 0-1.9 to be established. The scale was able to discriminate between conditions typically regarded as pruritic or non-pruritic. When the scale was assessed for its ability to detect changes in pruritus score following treatment, a median reduction of 4.4 points was observed. The scale was also used to determine what magnitude of response owners would expect following treatment of their pruritic dogs. Only 12% would have been satisfied with a 50% reduction, a figure that is typically quoted as a satisfactory response in clinical trials of anti-pruritic drugs. As a result, alternative methods of assessing clinical trials are proposed. This study has shown the scale to be a valuable tool for clinical assessment of patients, and for monitoring treatment responses in clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19171021     DOI: 10.1111/j.1365-3164.2008.00728.x

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  29 in total

1.  Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: A retrospective assessment of 8 cases.

Authors:  Chie Mogi; Masanori Yoshida; Koji Kawano; Takaaki Fukuyama; Toshiro Arai
Journal:  Can Vet J       Date:  2022-04       Impact factor: 1.075

2.  Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis.

Authors:  Eui-Hwa Nam; Seol-Hee Park; Ji-Young Jung; Seung-Hee Han; Hwa-Young Youn; Jun-Seok Chae; Cheol-Yong Hwang
Journal:  J Vet Sci       Date:  2012-06       Impact factor: 1.672

3.  The effect of long-term feeding of skin barrier-fortified diets on the owner-assessed incidence of atopic dermatitis symptoms in Labrador retrievers.

Authors:  Frank Looringh van Beeck; Adrian Watson; Margriet Bos; Vincent Biourge; Ton Willemse
Journal:  J Nutr Sci       Date:  2015-02-12

4.  Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double-blinded trial.

Authors:  M Eichenseer; C Johansen; R S Mueller
Journal:  Vet Rec       Date:  2013-10-10       Impact factor: 2.695

5.  LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy.

Authors:  John A Zebala; Alan Mundell; Linda Messinger; Craig E Griffin; Aaron D Schuler; Stuart J Kahn
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

6.  Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.

Authors:  Sallie B Cosgrove; Jody A Wren; Dawn M Cleaver; David D Martin; Kelly F Walsh; Jessica A Harfst; Stacey L Follis; Vickie L King; Joseph F Boucher; Michael R Stegemann
Journal:  Vet Dermatol       Date:  2013-07-05       Impact factor: 1.589

7.  Expression of barrier proteins in the skin lesions and inflammatory cytokines in peripheral blood mononuclear cells of atopic dogs.

Authors:  Sarita Kanwal; Shanker K Singh; Sandeep P Soman; Soumen Choudhury; Priyambada Kumari; Pradeep K Ram; Satish K Garg
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

8.  A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.

Authors:  Sallie B Cosgrove; Jody A Wren; Dawn M Cleaver; Kelly F Walsh; Stacey I Follis; Vickie I King; Jezaniah-Kira S Tena; Michael R Stegemann
Journal:  Vet Dermatol       Date:  2013-12       Impact factor: 1.589

9.  Successful nutritional control of scratching and clinical signs associated with adverse food reaction: A randomized controlled COSCAD'18 adherent clinical trial in dogs in the United States.

Authors:  James L Weemhoff; Jennifer M MacLeay; John Brejda; Heidi Schiefelbein; Susan M Wernimont; Kathy L Gross
Journal:  J Vet Intern Med       Date:  2021-06-11       Impact factor: 3.333

10.  Successful nutritional control of scratching and clinical signs associated with adverse food reaction: A randomized controlled COSCAD'18 adherent clinical trial in dogs in the United Kingdom.

Authors:  James L Weemhoff; Jennifer M MacLeay; John Brejda; Heidi Schiefelbein; Susan M Wernimont; Kathy L Gross
Journal:  J Vet Intern Med       Date:  2021-06-11       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.